Product logins

Find logins to all Clarivate products below.


Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Dry and Wet Age-Related Macular Degeneration (US)

The treatment of wet AMD in the United States has been mainly dominated by three anti-VEGF therapies: Roche / Genentech’s off-label Avastin, Roche / Genentech’s Lucentis, and Regeneron’s Eylea. The market is becoming increasingly fragmented; newer entrants Roche’s Vabysmo and Regeneron’s Eylea HD are being increasingly incorporated into the treatment algorithm of wet AMD patients, while competition from biosimilars grows. Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the management of wet AMD both among newly diagnosed patients and among patients filling a prescription for a key therapy.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed wet AMD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
  • How have Vabysmo and Eylea HD been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of wet AMD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of wet AMD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Roche / Genentech, Regeneron, Novartis, Biogen, Samsung Bioepis

Key drugs: Avastin, Eylea, Lucentis, Beovu, Mvasi, Zirabev, Vabysmo, Susvimo, Byooviz, Cimerli

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…